Press Releases

Results of the Placing and Open Offer

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN,...

View details

Placing and Open Offer of New Ordinary Shares

Click here to download the full Placing and Open Offer announcement THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY...

View details

Proposed Acquisitions of Aerocrine AB and Prosonix Limited Creating a World-Class Allergy and Asthma Specialty Pharma Business

Click here to download the full Proposed Acquisitions announcement NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN...

View details

Preliminary Results for the Year Ended 31 December 2014

Click here to download the full 2014 preliminary results statement – Strong clinical progress; Cat-SPIRE phase III study fully recruited – – Robust financial position; fully-funded to bring Cat-SPIRE to market – – Commercialisation preparations...

View details

Circassia Appoints Lota S Zoth as Non-Executive Director

Click here to download full press release Oxford, UK – 9 February 2015: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty biopharmaceutical company focused on allergy, today announces the appointment of Lota...

View details

Notice of Preliminary Results

Oxford, UK – 27 January 2015: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty biopharmaceutical company focused on allergy, will announce its preliminary results for the year ended 31 December 2014 on...

View details

Circassia Completes Recruitment for Cat Allergy Treatment Pivotal Phase III Study

Click here to download full press release – Study on track to report in H1 2016 – – 1,409 subjects randomised; 19% above target – Oxford, UK – 8 January 2015: Circassia Pharmaceuticals plc (“Circassia”...

View details

Circassia Announces Top-Line Results from Ragweed Allergy Treatment Phase IIb Chamber Study

Click to download full press release Oxford, UK – 8 December 2014: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty biopharmaceutical company focused on allergy, today announces results from a phase IIb...

View details

Circassia Interim Management Statement

Click here to download November 2014 Interim Management Statement – Strong operational progress; clinical programmes on track – – Encouraging results from third season follow-up study in grass allergy – Oxford, UK – 11 November...

View details

Interim Results for the Six Months Ended 30 June 2014

Click here to download the full 2014 interim results statement — Successfully raised over £200 million in landmark IPO — — Fully-funded to bring to market the first of a new generation of allergy immunotherapies...

View details